Equity Overview
Price & Market Data
Price: $1.11
Daily Change: +$0.01 / 0.90%
Daily Range: $1.10 - $1.20
Market Cap: $12,985,801
Daily Volume: 35,163
Performance Metrics
1 Week: -3.48%
1 Month: -30.62%
3 Months: -26.00%
6 Months: -11.55%
1 Year: -30.62%
YTD: -20.71%
Company Details
Employees: 1
Sector: Health technology
Industry: Biotechnology
Country:
Details
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.